GLP-1 medications are typically intended for long-term use, as their benefits diminish when discontinued
In chronic PD mice, the triple receptor agonist HM15211 protected against dopaminergic neuronal death, decreased -synuclein accumulation, and prevented nigrostriatal neurodegeneration by mitigating the inflammatory response and lipid peroxidation [124, 125]
What followed may prove to be a structural turning point not just for Novo, but for the entire compounded GLP-1 market and, by extension, for my other key holding, WW International
American Journal of Health-System Pharmacy
Other rare but serious complications include infection at the injection site (abscess formation) and, in isolated reports, neurological effects